Get the Stockscreener App
4.68
3.90%
-0.19
Polypid Ltd stock is traded at $4.68, with a volume of 72,823.
It is down -3.90% in the last 24 hours and up +7.59% over the past month.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
See More
Previous Close:
$4.87
Open:
$4.94
24h Volume:
72,823
Relative Volume:
0.90
Market Cap:
$77.85M
Revenue:
-
Net Income/Loss:
$-23.87M
P/E Ratio:
-0.2379
EPS:
-19.67
Net Cash Flow:
$-47.63M
1W Performance:
-2.50%
1M Performance:
+7.59%
6M Performance:
+37.24%
1Y Performance:
+58.11%
1-Day Range:
$4.675
$5.12
1-Week Range:
$4.52
$5.12
52-Week Range:
$2.30
$5.12
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
4.68 | 81.01M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.21 | 119.76B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
760.98 | 79.35B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
847.24 | 51.71B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
346.19 | 44.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
342.47 | 38.18B | 4.98B | 69.60M | 525.67M | 0.5198 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Initiated | Roth Capital | Buy |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Sep-14-21 | Initiated | JMP Securities | Mkt Outperform |
| Jul-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-24-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-10-20 | Initiated | Alliance Global Partners | Buy |
| Jul-21-20 | Initiated | BMO Capital Markets | Outperform |
| Jul-21-20 | Initiated | Barclays | Overweight |
| Jul-21-20 | Initiated | Raymond James | Outperform |
View All
Polypid Ltd Stock (PYPD) Latest News
Will PolyPid Ltd. stock recover after earningsJuly 2025 Volume & Low Volatility Stock Recommendations - Mfd.ru
PolyPid Ltd. (NASDAQ:PYPD) Sees Large Decrease in Short Interest - MarketBeat
PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026 - GlobeNewswire
PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Will PolyPid Gain Momentum Ahead Of Its NDA Filing? - RTTNews
Rate Hike: Will VF Corporation announce a stock splitWeekly Trade Summary & Reliable Price Action Trade Plans - baoquankhu1.vn
Aug Movers: Is AAME forming bullish engulfing patternsEarnings Trend Report & Consistent Profit Alerts - baoquankhu1.vn
Aug Movers: Will PolyPid Ltd stock recover after earnings2025 Technical Overview & Low Drawdown Momentum Ideas - baoquankhu1.vn
PolyPid calls February 2026 extraordinary meeting to approve board chair compensation - MSN
Aug Sentiment: Is PolyPid Ltd stock technically oversoldJuly 2025 Institutional & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
PYPD: D-PLEX 100's phase 3 success paves the way for FDA submission and U.S. commercialization - TradingView
Aug Catalysts: Will PolyPid Ltd stock return to pre crisis levels2025 Buyback Activity & Low Risk High Win Rate Picks - Bộ Nội Vụ
Why analysts remain bullish on PolyPid Ltd. stockQuarterly Risk Review & High Conviction Buy Zone Alerts - Улправда
Aug Big Picture: Can PolyPid Ltd. stock hit analyst price targetsJuly 2025 Earnings & Intraday High Probability Setup Alerts - Улправда
Will PolyPid Ltd. stock keep outperforming rivals2026 world cup usa national team group stage young talents high defensive line odds analysis expert opinion - ulpravda.ru
PolyPid Ltd. (NASDAQ:PYPD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PolyPid Ltd. (PYPD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market Moves: Can PolyPid Ltd stock sustain free cash flow growthForecast Cut & Accurate Entry/Exit Alerts - moha.gov.vn
Contrasting PolyPid (NASDAQ:PYPD) & Crinetics Pharmaceuticals (NASDAQ:CRNX) - Defense World
PolyPid Calls February 2026 Extraordinary Meeting to Approve Board Chair Compensation - TipRanks
PolyPid files for secondary offering - MSN
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Up 72.2% in December - MarketBeat
Value Recap: Will PolyPid Ltd. stock keep outperforming rivals2025 Market WrapUp & Stock Market Timing Techniques - Улправда
Will PolyPid Ltd. stock outperform international peersMarket Growth Review & Real-Time Volume Analysis Alerts - Улправда
Can PolyPid Ltd. stock sustain free cash flow growthQuarterly Growth Report & Step-by-Step Trade Execution Guides - DonanımHaber
Why PolyPid Ltd. stock attracts global investors2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - Улправда
Why PolyPid Ltd. stock could see breakout soonQuarterly Trade Review & Comprehensive Market Scan Insights - Улправда
PolyPid Appoints Brooke Story as Chairman Amid Strategic Growth - The Globe and Mail
Polypid names medtech veteran Brooke Story as board chairman - marketscreener.com
PolyPid Ltd. Appoints Brooke Story as Chairman of the Board of Directors - Quiver Quantitative
PolyPid (PYPD) appoints medtech veteran Brooke Story as board chairman - Stock Titan
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
PolyPid price target lowered to $9 from $10 at Roth Capital - MSN
PYPD: D-PLEX100 shows strong efficacy and safety for SSI prevention, with FDA filing planned for 2026 - TradingView — Track All Markets
Transcript : PolyPid Ltd.Special Call - marketscreener.com
PolyPid Ltd. (NASDAQ:PYPD) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
PolyPid Clears a Key FDA Milestone, Reducing Regulatory Risk Ahead of Its Planned NDA Filing (NASDAQ: PYPD) - TradingView — Track All Markets
PolyPid receives FDA support for D-PLEX100 NDA submission By Investing.com - Investing.com Australia
PolyPid Soars 3.4% on Pivotal FDA Endorsement for D-PLEX100 NDA - FinancialContent
PolyPid stock rises after FDA supports NDA submission for D-PLEX100 - Investing.com Nigeria
PolyPid stock rises after FDA supports NDA submission for D-PLEX100 By Investing.com - Investing.com South Africa
PolyPid receives FDA support for D-PLEX100 NDA submission - Investing.com
PolyPid Ltd. Announces Positive Fda Pre-Nda Meeting Minutes for D-Plex100 Supporting Nda Submission - marketscreener.com
Polypid announces positive FDA Pre-NDA meeting minutes - marketscreener.com
PolyPid Gains FDA Support for D-PLEX100 NDA Submission - TipRanks
PolyPid receives pre-NDA meeting minutes for D-Plex supporting NDA submission - TipRanks
PolyPid (NASDAQ: PYPD) highlights positive FDA pre-NDA minutes for D-PLEX100 NDA path - Stock Titan
Polypid Announces Positive FDA Pre-NDA Meeting Minutes - TradingView — Track All Markets
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission - GlobeNewswire
Polypid Ltd Stock (PYPD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):